Introduction And Importance: This case report describes a rare occurrence of ileocecal malignant lymphoma combined with adenocarcinoma, due to the low incidence rate of colonic malignant lymphoma.
Case Presentation: A 73-year-old female patient presented with abdominal pain and was diagnosed with "acute intussusception with intestinal obstruction" in the emergency department of our hospital. Due to the occurrence of intestinal obstruction the operation was performed, and postoperative pathology revealed a combination of ileocecal DLBCL and ascending colon adenocarcinoma at stage pT1N0M0. One month after the surgery, the patient received an R-CHOP chemotherapy regimen targeting the lymphoma from the hematology department of a local hospital. Upon reexamination after eight cycles of therapy, lymph nodes had enlarged and caused esophageal compression. Unfortunately, the patient contracted COVID-19 and was too weak to undergo any further targeted therapy treatment, and eventually passed away 17 months after the surgery.
Clinical Discussion: Synchronous cancers of the colon with malignant lymphoma and adenocarcinoma are rare but still exist. Emphasizing the importance of accurate diagnosis, this report aims to provide clinicians with a broad differential diagnosis, especially in cases where preoperative examination options are limited.
Conclusion: An accurate and comprehensive treatment plan should be tailored to the specific situations of different malignant tumors to improve the survival prognosis of patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543902 | PMC |
http://dx.doi.org/10.1016/j.ijscr.2024.110481 | DOI Listing |
Medicine (Baltimore)
January 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Rationale: Gastric antral vascular ectasia (GAVE) is a rare acquired lesion characterized by vascular dilation in the gastric antrum, frequently results in occult or overt gastrointestinal bleeding. Endoscopic intervention remains the cornerstone of therapy. Argon plasma coagulation was previously considered a first treatment option.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Internal Medicine, Division of Hematology and Oncology, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Rationale: Aggressive angiomyxoma (AAM) is an exceptionally rare mesenchymal tumor that predominantly manifests in the female genital organs during the reproductive age. Its rarity alone makes it a fascinating subject for study. The diagnosis of AAM necessitates differentiation from other benign or mesenchymal tumors and can be confirmed through immunohistochemistry (IHC) staining.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Neurology (Nerve-Muscle Unit), Reference Center for Neuromuscular Diseases "AOC," ALS Reference Center, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Rationale: Locked-in syndrome (and its variant, completely locked-in state) generally has a high mortality rate in the acute setting; however, when induced by conditions such as acute inflammatory polyradiculoneuropathy, it may well be curable such that an attempt at cure should be systematically sought by clinicians.
Patient Concerns: A 52-year-old man presented with acute tetraparesia and areflexia, initially diagnosed as Guillain-Barré syndrome. Despite appropriate treatment, his condition deteriorated, evolving into a completely locked-in state.
Medicine (Baltimore)
January 2025
Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, PR China.
Rationale: Bilateral gluteus medius contractures in adults are rare in clinical practice, with only a few cases reported. These contractures may result from repeated intramuscular injections during childhood. Understanding the clinical manifestations, diagnostic process, treatment, and outcomes can provide insights into effective management strategies.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Respiratory and Critical Care Medicine, Zhongshan City People's Hospital, Zhongshan, Guangdong Province, China.
Rationale: ROS proto-oncogene 1 (ROS1) fusion is a rare but important driver mutation in non-small cell lung cancer, which usually shows significant sensitivity to small molecule tyrosine kinase inhibitors. With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations of ROS1 have been discovered. Non-muscle myosin heavy chain 9 (MYH9) is a rare fusion partner of ROS1 gene as reported.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!